Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,375 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation.
Kurosawa S, Yamaguchi T, Mori A, Matsuura T, Masuko M, Murata M, Tashiro H, Kako S, Satake A, Hagihara M, Ota S, Saito T, Kagawa K, Matsuo Y, Itonaga H, Uoshima N, Yamaguchi H, Naito K, Takahashi M, Fukuda T. Kurosawa S, et al. Among authors: matsuo y. J Cancer Surviv. 2023 Jun;17(3):781-794. doi: 10.1007/s11764-022-01250-8. Epub 2022 Sep 1. J Cancer Surviv. 2023. PMID: 36048313
Risk factors for fatal cardiac complications after allogeneic hematopoietic cell transplantation: Japanese Society for Transplantation and Cellular Therapy transplant complications working group.
Yanagisawa R, Tamaki M, Tanoshima R, Misaki Y, Uchida N, Koi S, Tanaka T, Ozawa Y, Matsuo Y, Tanaka M, Ikegame K, Katayama Y, Matsuoka KI, Ara T, Kanda Y, Matsumoto K, Fukuda T, Atsuta Y, Kato M, Nakasone H. Yanagisawa R, et al. Among authors: matsuo y. Hematol Oncol. 2023 Aug;41(3):535-545. doi: 10.1002/hon.3101. Epub 2022 Nov 25. Hematol Oncol. 2023. PMID: 36385399
Risk factors and outcome of Stenotrophomonas maltophilia infection after allogeneic hematopoietic stem cell transplantation: JSTCT, Transplant Complications Working Group.
Saburi M, Oshima K, Takano K, Inoue Y, Harada K, Uchida N, Fukuda T, Doki N, Ikegame K, Matsuo Y, Katayama Y, Ozawa Y, Matsuoka KI, Kawakita T, Mori Y, Ara T, Nakamae H, Kimura T, Kanda Y, Atsuta Y, Ogata M; Transplant Complications Working Group of the Japanese Society for Transplantation and Cellular Therapy. Saburi M, et al. Among authors: matsuo y. Ann Hematol. 2023 Sep;102(9):2507-2516. doi: 10.1007/s00277-023-05320-4. Epub 2023 Jun 20. Ann Hematol. 2023. PMID: 37338625
The Confirmation of Safety for the Intensified Conditioning Regimens: A Retrospective Study of Allogeneic Hematopoietic Stem Cell Transplantation for Non-Remission Hematological Malignant Diseases.
Yoshida S, Henzan H, Ueno T, Shimakawa T, Matsuo Y, Kuriyama T, Saito N, Kawano I, Numata A, Takase K, Iino T, Eto T. Yoshida S, et al. Among authors: matsuo y. Int J Hematol Oncol Stem Cell Res. 2018 Apr 1;12(2):123-131. Int J Hematol Oncol Stem Cell Res. 2018. PMID: 30233774 Free PMC article.
Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era.
Ishida H, Shimada H, Tanizawa A, Shimazu Y, Tachibana T, Doki N, Ara T, Matsuo Y, Nara M, Toubai T, Ino K, Nakamae H, Kato K, Kato K, Sato A, Hino M, Matsumoto K, Atsuta Y, Yasui M, Nagamura-Inoue T. Ishida H, et al. Among authors: matsuo y. Am J Hematol. 2023 Aug;98(8):E200-E203. doi: 10.1002/ajh.26959. Epub 2023 May 12. Am J Hematol. 2023. PMID: 37170859 Free article.
Toxoplasmosis encephalitis following severe graft-vs.-host disease after allogeneic hematopoietic stem cell transplantation: 17 yr experience in Fukuoka BMT group.
Matsuo Y, Takeishi S, Miyamoto T, Nonami A, Kikushige Y, Kunisaki Y, Kamezaki K, Tu L, Hisaeda H, Takenaka K, Harada N, Kamimura T, Ohno Y, Eto T, Teshima T, Gondo H, Harada M, Nagafuji K. Matsuo Y, et al. Eur J Haematol. 2007 Oct;79(4):317-21. doi: 10.1111/j.1600-0609.2007.00919.x. Epub 2007 Aug 3. Eur J Haematol. 2007. PMID: 17680814
Oral valganciclovir as preemptive therapy is effective for cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients.
Takenaka K, Eto T, Nagafuji K, Kamezaki K, Matsuo Y, Yoshimoto G, Harada N, Yoshida M, Henzan H, Takase K, Miyamoto T, Akashi K, Harada M, Teshima T; for Fukuoka Blood and Marrow Transplant Group (FBMTG). Takenaka K, et al. Among authors: matsuo y. Int J Hematol. 2009 Mar;89(2):231-237. doi: 10.1007/s12185-008-0249-2. Epub 2009 Jan 17. Int J Hematol. 2009. PMID: 19148587 Clinical Trial.
The impact of hepatitis B core antibody levels on HBV reactivation after allogeneic hematopoietic SCT: an 11-year experience at a single center.
Bae SK, Gushima T, Saito N, Yamanaka I, Shimokawa T, Matsuo Y, Yoshida S, Kawano I, Henzan H, Shimoda S, Eto T, Takahashi K. Bae SK, et al. Among authors: matsuo y. Bone Marrow Transplant. 2016 Nov;51(11):1496-1498. doi: 10.1038/bmt.2016.149. Epub 2016 Jun 6. Bone Marrow Transplant. 2016. PMID: 27272453 No abstract available.
2,375 results